Biocartis – Clinical utility of Idylla EGFR

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge

Biocartis – Breast Cancer Portfolio

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Biocartis is pleased to launch a new breast cancer portfolio: Idylla™ PIK3CA-AKT1 Mutation Assay, APIS Breast Cancer Subtyping Kit and APIS ESR1 Mutations Kit.

SeptiCyte RAPID – available for IVD use in Australia

Products are for Professional/Laboratory use only Diagnose Sepsis with more certainty in just one hour with SeptiCyte® RAPID, now available for IVD use in Australia.

Biocartis Idylla™ IDH1-2 Mutation Assay Kit

Products are for professional/laboratory use only The Idylla IDH1-2 Mutation Assay Kit (RUO)1 can detect five mutations in the IDH1 gene and 10 mutations in the IDH2 gene, along with an integrated processing control. The turnaround time is approximately 95 minutes from sample to result. The assay performance has been evaluated at multiple sites in both […]

Biocartis Idylla™ GeneFusion Assay*

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections.

Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to